The effects of Zinc, vitamin D supplementation and co-supplementation of them versus placebo on adipokines and indicators related to metabolism in over weight and obese subjects

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201608082365N13

Enrollment

140

Registered

2016-08-26

Start date

2016-09-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Obesity due to excess calories

Interventions

Intervention 1: Intervention groups consume: (1) 2,000 U/day vitamin D + zinc placebo or (2) 30 mg/day zinc + vitamin D placebo or (3) 2,000 U/day vitamin D + 30 mg/day zinc every day for 12 weeks. In

Treatment - Drugs

Placebo

Intervention groups consume: (1) 2,000 U/day vitamin D + zinc placebo or (2) 30 mg/day zinc + vitamin D placebo or (3) 2,000 U/day vitamin D + 30 mg/day zinc every day for 12 weeks

Control group: Consume 2 pill placebo of vitamin D and zinc contained maltodextrin ("Roshd" Pharmaceutical Incubation Center of Tehran University of Medical Sciences) every day for 12 weeks

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age between 20 to 60 years old; BMI greater than 27; willing to participate; weight stable in 3 last months. Exclusion criteria: having a history of coronary artery disease; acute or chronic renal failure; acute or chronic hepatic failure; presence of any chronic inflammatory and autoimmune disease; and any known malignancy; hormone therapy; other non-pathological exclusion criteria included pregnancy; breast feeding; post-menopause; smoking, professional athlete; uncontrolled thyroid disorder; use of medications for dyslipidemia or hypertension; having a special diet for any reason prescribed by the clinic dietitian; consumption of nutritional supplements within the past 12 weeks.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum level of leptin. Timepoint: Before and 12 weeks after intervention. Method of measurement: Serum concentration of leptin with Laboratory Kit.	—

Secondary

Measure	Time frame
Insulin-like growth factor-1. Timepoint: Before and 12 weeks after intervention. Method of measurement: Serum concentration with Laboratory Kit (Mediagnose; Germany).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Reza Vafa

Iran University of Medical Sciences

vafa.m@iums.ac.ir+98 21 8670 4734

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026